108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
糖皮质激素诱发的白内障
Authors Jian YF, Zhang JS , Wan XH
Received 6 May 2025
Accepted for publication 12 September 2025
Published 6 October 2025 Volume 2025:19 Pages 3703—3712
DOI https://doi.org/10.2147/OPTH.S537700
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Yu-Feng Jian, Jing-Shang Zhang, Xiu-Hua Wan
Beijing Tongren Eye Center, Beijing Tongren Hospital of Capital Medical University, Beijing Key Laboratory of Ophthalmology and Vision Science, Beijing, 100730, People’s Republic of China
Correspondence: Xiu-Hua Wan, Email wanxh@ccmu.edu.cn Jing-Shang Zhang, Email jszhang@ccmu.edu.cn
Abstract: Glucocorticoids (GCs) remain a cornerstone therapy for noninfectious uveitis and autoimmune disorders; however, chronic administration is strongly associated with sight-threatening complications, particularly glucocorticoid-induced cataracts (GIC). This comprehensive review synthesizes current evidence on the molecular pathogenesis, epidemiological patterns, and clinical management of GIC. Epidemiological analyses indicate that over 50% of patients receiving systemic corticosteroids for > 60 days develop ocular complications, with cataract formation (36%) and glaucoma (16%) representing the predominant sequelae. Histopathologically, GIC manifests as posterior subcapsular opacities, mechanistically linked to oxidative stress, epithelial-mesenchymal transition (EMT), vimentin dysregulation, Na+/K+-ATPase inhibition, apoptosis, and endoplasmic reticulum (ER) stress. Risk stratification models identify cumulative GC dose (> 20,000 mg/m² prednisolone equivalents), treatment duration (> 6 months), and administration route (oral > topical > intravitreal) as critical determinants of cataractogenesis. Although early-stage GIC is clinically silent, progressive opacification leads to debilitating visual acuity loss, photophobia, and impaired quality of life. Current interventions encompass antioxidants, molecular targeting strategies, advanced drug delivery systems, and glucocorticoid-sparing agents. Through systematic integration of epidemiology, pathogenesis, and therapeutic advances, we aim to resolve the GC therapeutic paradox and provide robust frameworks for future clinical management.
Keywords: glucocorticoid, glucocorticoid induced cataract, intervention
Beijing Tongren Eye Center, Beijing Tongren Hospital of Capital Medical University, Beijing Key Laboratory of Ophthalmology and Vision Science, Beijing, 100730, People’s Republic of China
Correspondence: Xiu-Hua Wan, Email wanxh@ccmu.edu.cn Jing-Shang Zhang, Email jszhang@ccmu.edu.cn
Abstract: Glucocorticoids (GCs) remain a cornerstone therapy for noninfectious uveitis and autoimmune disorders; however, chronic administration is strongly associated with sight-threatening complications, particularly glucocorticoid-induced cataracts (GIC). This comprehensive review synthesizes current evidence on the molecular pathogenesis, epidemiological patterns, and clinical management of GIC. Epidemiological analyses indicate that over 50% of patients receiving systemic corticosteroids for > 60 days develop ocular complications, with cataract formation (36%) and glaucoma (16%) representing the predominant sequelae. Histopathologically, GIC manifests as posterior subcapsular opacities, mechanistically linked to oxidative stress, epithelial-mesenchymal transition (EMT), vimentin dysregulation, Na+/K+-ATPase inhibition, apoptosis, and endoplasmic reticulum (ER) stress. Risk stratification models identify cumulative GC dose (> 20,000 mg/m² prednisolone equivalents), treatment duration (> 6 months), and administration route (oral > topical > intravitreal) as critical determinants of cataractogenesis. Although early-stage GIC is clinically silent, progressive opacification leads to debilitating visual acuity loss, photophobia, and impaired quality of life. Current interventions encompass antioxidants, molecular targeting strategies, advanced drug delivery systems, and glucocorticoid-sparing agents. Through systematic integration of epidemiology, pathogenesis, and therapeutic advances, we aim to resolve the GC therapeutic paradox and provide robust frameworks for future clinical management.
Keywords: glucocorticoid, glucocorticoid induced cataract, intervention